The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory

Vaccines based on mRNA-containing lipid nanoparticles (LNPs) are a promising new platform used by two leading vaccines against COVID-19. Clinical trials and ongoing vaccinations present with varying degrees of protection levels and side effects. However, the drivers of the reported side effects rema...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:iScience Jg. 24; H. 12; S. 103479
Hauptverfasser: Ndeupen, Sonia, Qin, Zhen, Jacobsen, Sonya, Bouteau, Aurélie, Estanbouli, Henri, Igyártó, Botond Z.
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States Elsevier Inc 17.12.2021
Elsevier
Schlagworte:
Biological sciences
Biotechnology
Immunology
Biotechnology
Biological sciences
Immunology
ISSN:2589-0042, 2589-0042
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Vaccines based on mRNA-containing lipid nanoparticles (LNPs) are a promising new platform used by two leading vaccines against COVID-19. Clinical trials and ongoing vaccinations present with varying degrees of protection levels and side effects. However, the drivers of the reported side effects remain poorly defined. Here we present evidence that Acuitas' LNPs used in preclinical nucleoside-modified mRNA vaccine studies are highly inflammatory in mice. Intradermal and intramuscular injection of these LNPs led to rapid and robust inflammatory responses, characterized by massive neutrophil infiltration, activation of diverse inflammatory pathways, and production of various inflammatory cytokines and chemokines. The same dose of LNP delivered intranasally led to similar inflammatory responses in the lung and resulted in a high mortality rate, with mechanism unresolved. Thus, the mRNA-LNP platforms' potency in supporting the induction of adaptive immune responses and the observed side effects may stem from the LNPs' highly inflammatory nature. [Display omitted] •Lipid nanoparticles (LNPs) used for preclinical studies are highly inflammatory•The LNPs activate multiple inflammatory pathways and induce IL-1β and IL-6•The LNPs' inflammatory properties stem from their ionizable lipid component•The LNPs could be responsible for adjuvanticity and some of the side effects Biological sciences; Immunology; Biotechnology
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors contributed equally
Lead contact
ISSN:2589-0042
2589-0042
DOI:10.1016/j.isci.2021.103479